Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study
Although several antidiabetic agents are currently available, they commonly have undesirable effects and are not fully effective in reducing blood glucose. Therefore, since a long time ago, some Indonesians have preferred herbal medicine to cure and prevent diseases such as Lagerstroemia speciosa (L...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Penerbit Universiti Kebangsaan Malaysia
2023
|
| Online Access: | http://journalarticle.ukm.my/23361/ http://journalarticle.ukm.my/23361/1/SD%2012.pdf |
| _version_ | 1848815826999705600 |
|---|---|
| author | Tan, Santi Tjandrawinata, Raymond Rubianto Prasasty, Vivitri Dewi |
| author_facet | Tan, Santi Tjandrawinata, Raymond Rubianto Prasasty, Vivitri Dewi |
| author_sort | Tan, Santi |
| building | UKM Institutional Repository |
| collection | Online Access |
| description | Although several antidiabetic agents are currently available, they commonly have undesirable effects and are not fully effective in reducing blood glucose. Therefore, since a long time ago, some Indonesians have preferred herbal medicine to cure and prevent diseases such as Lagerstroemia speciosa (L.) Pers. and Cinnamomum burmanni. (Nees & T.Nees) Blume, plants from Indonesia, are believed to be able to treat type 2 diabetes mellitus (T2DM). Both herbs are present in DLBS3233 bioactive fraction, a standardized herbal extract that acts as an insulin sensitizer like thiazolidinediones (TZDs). However, the molecular mechanisms, the bioactive compounds, and the target proteins involved remain unclear. To understand more about the potential molecular mechanism of DLBS3233 in treating T2DM, this network pharmacology study is conducted for the first time. Quercetin, kaempferol, and ellagic acid were discovered to have antidiabetic effects in this study as selected compounds of DLBS3233, p rimarily o n e ight c ore target proteins, including AKT1, EGFR, GSK3B, IL6, PTK2, RELA, SRC, and VEGFA. We also found that they exhibited ligand-receptor binding activity comparable to pioglitazone in the molecular docking study. Concisely, as a reference for furthering the development of this bioactive fraction, this study provides novel information on DLBS3233 in T2DM treatment that was not shown in prior studies. |
| first_indexed | 2025-11-15T00:56:09Z |
| format | Article |
| id | oai:generic.eprints.org:23361 |
| institution | Universiti Kebangasaan Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T00:56:09Z |
| publishDate | 2023 |
| publisher | Penerbit Universiti Kebangsaan Malaysia |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | oai:generic.eprints.org:233612024-04-19T03:10:49Z http://journalarticle.ukm.my/23361/ Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study Tan, Santi Tjandrawinata, Raymond Rubianto Prasasty, Vivitri Dewi Although several antidiabetic agents are currently available, they commonly have undesirable effects and are not fully effective in reducing blood glucose. Therefore, since a long time ago, some Indonesians have preferred herbal medicine to cure and prevent diseases such as Lagerstroemia speciosa (L.) Pers. and Cinnamomum burmanni. (Nees & T.Nees) Blume, plants from Indonesia, are believed to be able to treat type 2 diabetes mellitus (T2DM). Both herbs are present in DLBS3233 bioactive fraction, a standardized herbal extract that acts as an insulin sensitizer like thiazolidinediones (TZDs). However, the molecular mechanisms, the bioactive compounds, and the target proteins involved remain unclear. To understand more about the potential molecular mechanism of DLBS3233 in treating T2DM, this network pharmacology study is conducted for the first time. Quercetin, kaempferol, and ellagic acid were discovered to have antidiabetic effects in this study as selected compounds of DLBS3233, p rimarily o n e ight c ore target proteins, including AKT1, EGFR, GSK3B, IL6, PTK2, RELA, SRC, and VEGFA. We also found that they exhibited ligand-receptor binding activity comparable to pioglitazone in the molecular docking study. Concisely, as a reference for furthering the development of this bioactive fraction, this study provides novel information on DLBS3233 in T2DM treatment that was not shown in prior studies. Penerbit Universiti Kebangsaan Malaysia 2023 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/23361/1/SD%2012.pdf Tan, Santi and Tjandrawinata, Raymond Rubianto and Prasasty, Vivitri Dewi (2023) Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study. Sains Malaysiana, 52 (12). pp. 3497-3509. ISSN 0126-6039 https://www.ukm.my/jsm/english_journals/vol52num12_2023/contentsVol52num12_2023.html |
| spellingShingle | Tan, Santi Tjandrawinata, Raymond Rubianto Prasasty, Vivitri Dewi Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study |
| title | Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study |
| title_full | Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study |
| title_fullStr | Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study |
| title_full_unstemmed | Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study |
| title_short | Molecular mechanism of DLBS3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study |
| title_sort | molecular mechanism of dlbs3233 bioactive fraction in type-2 diabetes mellitus: network pharmacology and docking study |
| url | http://journalarticle.ukm.my/23361/ http://journalarticle.ukm.my/23361/ http://journalarticle.ukm.my/23361/1/SD%2012.pdf |